Literature DB >> 2880735

Effects of the enantiomers of MDA, MDMA and related analogues on [3H]serotonin and [3H]dopamine release from superfused rat brain slices.

M P Johnson, A J Hoffman, D E Nichols.   

Abstract

The primary amines 3,4-methylenedioxyamphetamine (MDA), and 1-(1,3-benzodioxol-5-yl)-2-butanamine (BDB) were measured for efficacy in release of [3H]serotonin (5-HT) from rat hippocampal slices, and release of [3H]dopamine (DA) from rat caudate nucleus slices. The N-methyl derivatives of MDA and BDB, MDMA and MBDB, respectively, and the optical antipodes of these four agents were compared in this paradigm. All of the test compounds demonstrated a similar efficacy of [3H]5-HT release in the micromolar concentration range. No significant stereoselectivity was seen in measurements of 5-HT release. However, striking differences were found between the test compounds when [3H]DA release was studied. N-methylation of racemic MDA resulted in a decreased ability to release DA, while side chain extension from alpha-methyl to alpha-ethyl completely abolished this activity. Stereoselectivity for the S-(+)-isomers of MDA and MDMA was also demonstrated in the DA release studies. Correlation of these biochemical findings with human subjective reports indicates that serotonin release may play a more important role in the mechanism of action than does dopamine release.

Entities:  

Mesh:

Substances:

Year:  1986        PMID: 2880735     DOI: 10.1016/0014-2999(86)90615-1

Source DB:  PubMed          Journal:  Eur J Pharmacol        ISSN: 0014-2999            Impact factor:   4.432


  43 in total

1.  Reduced 3,4-methylenedioxymethamphetamine (MDMA, Ecstasy)-initiated oxidative DNA damage and neurodegeneration in prostaglandin H synthase-1 knockout mice.

Authors:  Winnie Jeng; Peter G Wells
Journal:  ACS Chem Neurosci       Date:  2010-02-23       Impact factor: 4.418

2.  3,4-Methylenedioxymethamphetamine enhances the release of acetylcholine in the prefrontal cortex and dorsal hippocampus of the rat.

Authors:  Sunila G Nair; Gary A Gudelsky
Journal:  Psychopharmacology (Berl)       Date:  2005-12-24       Impact factor: 4.530

3.  MDMA-induced loss of parvalbumin interneurons within the dentate gyrus is mediated by 5HT2A and NMDA receptors.

Authors:  Stuart A Collins; Gary A Gudelsky; Bryan K Yamamoto
Journal:  Eur J Pharmacol       Date:  2015-04-30       Impact factor: 4.432

Review 4.  Dark Classics in Chemical Neuroscience: 3,4-Methylenedioxymethamphetamine.

Authors:  Lee E Dunlap; Anne M Andrews; David E Olson
Journal:  ACS Chem Neurosci       Date:  2018-07-12       Impact factor: 4.418

5.  Stereochemistry of mephedrone neuropharmacology: enantiomer-specific behavioural and neurochemical effects in rats.

Authors:  Ryan A Gregg; Michael H Baumann; John S Partilla; Julie S Bonano; Alexandre Vouga; Christopher S Tallarida; Venkata Velvadapu; Garry R Smith; M Melissa Peet; Allen B Reitz; S Stevens Negus; Scott M Rawls
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

6.  MDMA produces stimulant-like conditioned locomotor activity.

Authors:  L H Gold; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

7.  A role for the mesolimbic dopamine system in the psychostimulant actions of MDMA.

Authors:  L H Gold; C B Hubner; G F Koob
Journal:  Psychopharmacology (Berl)       Date:  1989       Impact factor: 4.530

Review 8.  Acute and long-term effects of MDMA on cerebral dopamine biochemistry and function.

Authors:  M Isabel Colado; Esther O'Shea; A Richard Green
Journal:  Psychopharmacology (Berl)       Date:  2004-04-09       Impact factor: 4.530

9.  MDMA produces a delayed and sustained increase in the extracellular concentration of glutamate in the rat hippocampus.

Authors:  John H Anneken; Gary A Gudelsky
Journal:  Neuropharmacology       Date:  2012-07-25       Impact factor: 5.250

10.  Amphetamine derivatives induce locomotor hyperactivity by acting as indirect serotonin agonists.

Authors:  C W Callaway; M P Johnson; L H Gold; D E Nichols; M A Geyer
Journal:  Psychopharmacology (Berl)       Date:  1991       Impact factor: 4.530

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.